Lipopolysaccharide and TNF-alpha activate the nuclear factor kappa B pathway in the human placental JEG-3 cells

Placenta. 2006 Jun-Jul;27(6-7):568-75. doi: 10.1016/j.placenta.2005.06.003. Epub 2005 Aug 24.

Abstract

Up-regulation of pro-inflammatory cytokines, cyclooxygenase (COX-2) and prostaglandins is a critical factor driving human term labour and inflammation-associated preterm labour. Nuclear factor kappa B (NF-kappaB) is activated in response to a number of inflammatory mediators, including cytokines and lipopolysaccharide (LPS). The aim of this study was (i) to investigate if TNF-alpha and LPS activate the NF-kappaB pathway; and (ii) to use short interfering RNA (siRNA) against inhibitor kappaB kinase (IKK)-beta to confirm the role of the NF-kappaB pathway in the regulation of pro-inflammatory mediators in human placental JEG-3 cells. JEG-3 cells (3 independent experiments) were (i) incubated in the presence or absence of 10 microg/ml LPS or 20 ng/ml TNF-alpha, or (ii) transfected with 100 nM IKK-beta siRNA. Incubation of JEG-3 cells with LPS and TNF-alpha increased the expression of cytoplasmic IKK-beta and phosphorylated IkappaB-alpha, and nuclear NF-kappaB proteins p50 and p65. This was associated with a concurrent increase in COX-2 protein, and IL-6 and PGF2alpha release from JEG-3 cells. Treatment of cells with BAY 11-7082 at 50 microM significantly inhibited basal, LPS- and TNF-alpha-induced NF-kappaB and COX-2 expression, and IL-6 and PGF2alpha release. Transfection of JEG-3 cells with IKK-beta siRNA significantly decreased IL-6 and PGF2alpha release. The data presented in this study demonstrate that pro-inflammatory mediators regulate the NF-kappaB transcription pathway in human JEG-3 cells, and the IKK-beta/NF-kappaB pathway is a regulator of inflammatory mediators in placental JEG-3 cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Choriocarcinoma / drug therapy
  • Choriocarcinoma / genetics
  • Choriocarcinoma / metabolism*
  • Cyclooxygenase 2 / metabolism
  • Dinoprost / metabolism
  • Dose-Response Relationship, Drug
  • Drug Combinations
  • Humans
  • I-kappa B Kinase / genetics
  • I-kappa B Kinase / metabolism
  • Interleukin-6 / metabolism
  • Lipopolysaccharides / pharmacology*
  • Membrane Proteins / metabolism
  • NF-kappa B / antagonists & inhibitors
  • NF-kappa B / biosynthesis*
  • NF-kappa B / genetics
  • Nitriles / pharmacology
  • RNA, Small Interfering / pharmacology
  • Sulfones / pharmacology
  • Transfection
  • Trophoblasts / drug effects
  • Trophoblasts / metabolism*
  • Tumor Necrosis Factor-alpha / pharmacology*

Substances

  • 3-(4-methylphenylsulfonyl)-2-propenenitrile
  • Drug Combinations
  • Interleukin-6
  • Lipopolysaccharides
  • Membrane Proteins
  • NF-kappa B
  • Nitriles
  • RNA, Small Interfering
  • Sulfones
  • Tumor Necrosis Factor-alpha
  • Dinoprost
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • I-kappa B Kinase